BioMarin Pharmaceutical reported 21.07 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
Acadia Pharmaceuticals 11.33 1.25 Jun/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 75.64 4.4 Jun/2026
Amgen 18.07 1.77 Jun/2026
Bayer 3.4 8.75 Mar/2026
Biogen 23.23 9.53 Jun/2026
BioMarin Pharmaceutical 21.07 5.79 Jun/2026
Gilead Sciences 13.51 4.2 Jun/2026
Incyte 14.45 0.9 Jun/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 22.1 5.99 Jun/2026
PTC Therapeutics 8.76 1.22 Mar/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 20.87 5.12 Mar/2026
Sarepta Therapeutics 27.27 0 Mar/2026
United Therapeutics 19.15 1.27 Jun/2026
Vertex Pharmaceuticals 28.05 2.22 Jun/2026